553 related articles for article (PubMed ID: 20668036)
1. Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers.
Fassnacht M; Johanssen S; Fenske W; Weismann D; Agha A; Beuschlein F; Führer D; Jurowich C; Quinkler M; Petersenn S; Spahn M; Hahner S; Allolio B;
J Clin Endocrinol Metab; 2010 Nov; 95(11):4925-32. PubMed ID: 20668036
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma.
Fassnacht M; Hahner S; Polat B; Koschker AC; Kenn W; Flentje M; Allolio B
J Clin Endocrinol Metab; 2006 Nov; 91(11):4501-4. PubMed ID: 16895957
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant mitotane treatment for adrenocortical carcinoma.
Terzolo M; Angeli A; Fassnacht M; Daffara F; Tauchmanova L; Conton PA; Rossetto R; Buci L; Sperone P; Grossrubatscher E; Reimondo G; Bollito E; Papotti M; Saeger W; Hahner S; Koschker AC; Arvat E; Ambrosi B; Loli P; Lombardi G; Mannelli M; Bruzzi P; Mantero F; Allolio B; Dogliotti L; Berruti A
N Engl J Med; 2007 Jun; 356(23):2372-80. PubMed ID: 17554118
[TBL] [Abstract][Full Text] [Related]
4. Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection.
Terzolo M; Baudin AE; Ardito A; Kroiss M; Leboulleux S; Daffara F; Perotti P; Feelders RA; deVries JH; Zaggia B; De Francia S; Volante M; Haak HR; Allolio B; Al Ghuzlan A; Fassnacht M; Berruti A
Eur J Endocrinol; 2013 Sep; 169(3):263-70. PubMed ID: 23704714
[TBL] [Abstract][Full Text] [Related]
5. The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane.
Wängberg B; Khorram-Manesh A; Jansson S; Nilsson B; Nilsson O; Jakobsson CE; Lindstedt S; Odén A; Ahlman H
Endocr Relat Cancer; 2010 Mar; 17(1):265-72. PubMed ID: 20026647
[TBL] [Abstract][Full Text] [Related]
6. Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer.
Berruti A; Fassnacht M; Haak H; Else T; Baudin E; Sperone P; Kroiss M; Kerkhofs T; Williams AR; Ardito A; Leboulleux S; Volante M; Deutschbein T; Feelders R; Ronchi C; Grisanti S; Gelderblom H; Porpiglia F; Papotti M; Hammer GD; Allolio B; Terzolo M
Eur Urol; 2014 Apr; 65(4):832-8. PubMed ID: 24268504
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma.
Berruti A; Grisanti S; Pulzer A; Claps M; Daffara F; Loli P; Mannelli M; Boscaro M; Arvat E; Tiberio G; Hahner S; Zaggia B; Porpiglia F; Volante M; Fassnacht M; Terzolo M
J Clin Endocrinol Metab; 2017 Apr; 102(4):1358-1365. PubMed ID: 28324035
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence.
Calabrese A; Basile V; Puglisi S; Perotti P; Pia A; Saba L; Berchialla P; Porpiglia F; Veltri A; Volante M; Reimondo G; Berruti A; Terzolo M
Eur J Endocrinol; 2019 Jun; 180(6):387-396. PubMed ID: 30991359
[TBL] [Abstract][Full Text] [Related]
9. Risk of adrenocortical carcinoma in adrenal tumours greater than 8 cm.
Abdel-Aziz TE; Rajeev P; Sadler G; Weaver A; Mihai R
World J Surg; 2015 May; 39(5):1268-73. PubMed ID: 25526921
[TBL] [Abstract][Full Text] [Related]
10. Adrenocortical carcinoma: Retrospective analysis of the last 22 years.
Guelho D; Paiva I; Vieira A; Carrilho F
Endocrinol Nutr; 2016 May; 63(5):212-9. PubMed ID: 26969077
[TBL] [Abstract][Full Text] [Related]
11. Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane.
Grubbs EG; Callender GG; Xing Y; Perrier ND; Evans DB; Phan AT; Lee JE
Ann Surg Oncol; 2010 Jan; 17(1):263-70. PubMed ID: 19851811
[TBL] [Abstract][Full Text] [Related]
12. Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study.
Weigand I; Altieri B; Lacombe AMF; Basile V; Kircher S; Landwehr LS; Schreiner J; Zerbini MCN; Ronchi CL; Megerle F; Berruti A; Canu L; Volante M; Paiva I; Della Casa S; Sbiera S; Fassnacht M; Fragoso MCBV; Terzolo M; Kroiss M
J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32449514
[TBL] [Abstract][Full Text] [Related]
13. Long-term survival after adrenalectomy for stage I/II adrenocortical carcinoma (ACC): a retrospective comparative cohort study of laparoscopic versus open approach.
Donatini G; Caiazzo R; Do Cao C; Aubert S; Zerrweck C; El-Kathib Z; Gauthier T; Leteurtre E; Wemeau JL; Vantyghem MC; Carnaille B; Pattou F
Ann Surg Oncol; 2014 Jan; 21(1):284-91. PubMed ID: 24046101
[TBL] [Abstract][Full Text] [Related]
14. Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma.
Megerle F; Herrmann W; Schloetelburg W; Ronchi CL; Pulzer A; Quinkler M; Beuschlein F; Hahner S; Kroiss M; Fassnacht M;
J Clin Endocrinol Metab; 2018 Apr; 103(4):1686-1695. PubMed ID: 29452402
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant radiation therapy improves local control after surgical resection in patients with localized adrenocortical carcinoma.
Sabolch A; Else T; Griffith KA; Ben-Josef E; Williams A; Miller BS; Worden F; Hammer GD; Jolly S
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):252-9. PubMed ID: 25754631
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group.
Postlewait LM; Ethun CG; Tran TB; Prescott JD; Pawlik TM; Wang TS; Glenn J; Hatzaras I; Shenoy R; Phay JE; Keplinger K; Fields RC; Jin LX; Weber SM; Salem A; Sicklick JK; Gad S; Yopp AC; Mansour JC; Duh QY; Seiser N; Solorzano CC; Kiernan CM; Votanopoulos KI; Levine EA; Staley CA; Poultsides GA; Maithel SK
J Am Coll Surg; 2016 Apr; 222(4):480-90. PubMed ID: 26775162
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma.
Else T; Williams AR; Sabolch A; Jolly S; Miller BS; Hammer GD
J Clin Endocrinol Metab; 2014 Feb; 99(2):455-61. PubMed ID: 24302750
[TBL] [Abstract][Full Text] [Related]
18. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group.
Icard P; Goudet P; Charpenay C; Andreassian B; Carnaille B; Chapuis Y; Cougard P; Henry JF; Proye C
World J Surg; 2001 Jul; 25(7):891-7. PubMed ID: 11572030
[TBL] [Abstract][Full Text] [Related]
19. Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma.
Gonzalez RJ; Tamm EP; Ng C; Phan AT; Vassilopoulou-Sellin R; Perrier ND; Evans DB; Lee JE
Surgery; 2007 Dec; 142(6):867-75; discussion 867-75. PubMed ID: 18063070
[TBL] [Abstract][Full Text] [Related]
20. Combination of Mitotane and Locoregional Treatments in Low-volume Metastatic Adrenocortical Carcinoma.
Boilève A; Mathy E; Roux C; Faron M; Hadoux J; Tselikas L; Al Ghuzlan A; Hescot S; Leboulleux S; de Baere T; Lamartina L; Deschamps F; Baudin E
J Clin Endocrinol Metab; 2021 Oct; 106(11):e4698-e4707. PubMed ID: 34143888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
